To assess the impact of live CBM588 on the efficacy of anti-PD-1 therapy in mice, we took advantage of an established syngeneic LL-2 lung adenocarcinoma that leads to the outgrowth of resistant tumor to PD-1 blockade.15 The subcutaneous implantation of such poorly immunogenic LL-2 cells give rise to a tumor that reaches a volume of 35 to 50 mm3 within seven days. The gene discussed is PDCD1; the disease is neoplasm.